$2.42
-0.04(-1.83%)
Mkt Cap $278M
$0.62
$6.56
52-Week Range
At a Glance
AI-generatedRevenue breakdown: Licensing And Collaboration (100%).
6-K
NovaBridge announced a productive FDA Type B meeting confirming givastomig’s potential eligibility for an accelerated approval pathway in 1L Her2-, CLDN18.2+, PD-L1+ GEC, based on positive Phase 1b data. The company intends to initiate a registrational Phase 3 combination trial as early as Q4 2026 using ORR as the primary endpoint.$278M
Market Cap
—
Revenue
-$522M
Net Income
Employees32
Fundamentals
How The Business Makes Money
Revenue by Segment
Licensing And Collaboration100%($632.0K)
Activity
What Changed Recently
Company Profile
CIK0001778016
ISINUS44975P1030
CUSIP44975P103
Phone240 745 6330
Address2440 Research Boulevard, Rockville, MD, 20850, US
SEC EDGAR